التفاصيل البيبلوغرافية
| العنوان: |
Platelet-derived growth factors from a single donor by apheresis and one freeze–thaw cycle for treating medication-related osteonecrosis of the jaw. |
| المؤلفون: |
Vidán-Estévez, Julia, Escalante-Barrigón, Fernando, Sánchez-Herráez, Sergio, Seco-Calvo, Jesús |
| المصدر: |
Regenerative Medicine; Dec2022, Vol. 17 Issue 12, p915-929, 15p |
| مستخلص: |
Aim: To assess whether the use of allogeneic platelet-derived growth factors could serve as a feasible, effective and safe biological therapy for the treatment of medication-related osteonecrosis of the jaw (MRONJ). Materials & methods: Patients with multiple myeloma and MRONJ were included and treated with allogeneic platelet-rich plasma, continued for between 6 and 18 weeks (mean: 9). Results: We observed a treatment success rate of 87.5% (p < 0.05). Assessing the association between healing and treatment duration, we observed a statistically significant relationship (χ2 = 8.00; p = 0.018; Cramer's V = 1), confirming that healing was very closely related to the duration of the treatment. Conclusion: Allogeneic platelet-rich plasma could be a recommended treatment for MRONJ. Future research with a large sample to validate our findings is required. [ABSTRACT FROM AUTHOR] |
|
Copyright of Regenerative Medicine is the property of Taylor & Francis Ltd and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
